Results 1 to 10 of about 15,543 (118)

Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study [PDF]

Breast
Background: Breast cancer (BC) is the most commonly diagnosed cancer among women, with 30% of cases occurring at age ≥70 years (70+). Because patients 70+ are underrepresented in BC clinical trials, real-world data may help fill treatment knowledge gaps ...
E. Carola, P. Caillet, C. Falandry, L. Tassy, E. Paillaud, M. Pulido, G. Rochette de Lempdes, M. Bringuier, N. Jovenin, A. Boudrant, J. Grosjean, C. Chakiba-Brugere, O. Guillem, AC Hardy Bessard, H. Orfeuvre, E. Legouffe, Y. Brault, C. Chen, A. Coumert, M. Decrop, F. Bouteiller, E. Brain   +21 more
doaj   +2 more sources

Ribociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study [PDF]

Cancer Reports
Background Cyclin‐dependent kinase (CDK) 4/6 inhibitors are standard for treating hormone receptor‐positive metastatic breast cancer when combined with endocrine therapy. However, comparisons of first‐line treatments are scarce.
Cheng‐Wei Chou, Yi‐Hung Lo, Chia‐I. Wei, Chiann‐Yi Hsu, Chih‐Chiang Hung, Yen‐Dun Tzeng, Chia‐Hua Liu   +6 more
doaj   +2 more sources

Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma

Journal of the Formosan Medical Association, 2021
Background/purpose: Palbociclib is an FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitor that has been clinically proven to be effective in breast cancer. However, its use in oral cancer is not well researched.
Tong-Hong Wang, Chin-Chuan Chen, Yann-Lii Leu, Yun-Shien Lee, Jang-Hau Lian, Hsi-Lung Hsieh, Chi-Yuan Chen   +6 more
doaj   +1 more source

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects

Pharmaceutics, 2022
Palbociclib is a good candidate for therapeutic drug monitoring (TDM) due to its narrow therapeutic range and frequency of toxicities, particularly high-grade neutropenia.
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, Marie Alexandre, Séverine Guiu, Nelly Firmin, Stéphane Pouderoux, Marie Viala, Gerald Lossaint, Chloé Gautier, Caroline Mollevi, Matthieu Gracia, Celine Gongora, Litaty Mbatchi, Alexandre Evrard, William Jacot   +15 more
doaj   +1 more source

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer

Cell Death Discovery, 2023
Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii ...
Xianzhe Wang, Wei Shi, Xumei Wang, Jin-Jian Lu, Ping He, Hongjie Zhang, Xiuping Chen   +6 more
doaj   +1 more source

Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation

Current Oncology, 2022
Lung squamous cell carcinoma (LUSC) treatment response is poor and treatment alternatives are limited. Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, has recently been approved for hormone receptor-positive breast cancer patients and applied
Wenjing Xiang, Wanchen Qi, Huayu Li, Jia Sun, Chao Dong, Haojie Ou, Bing Liu   +6 more
doaj   +1 more source

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

Frontiers in Pharmacology, 2022
Palbociclib was approved by the United States Food and Drug Administration for use, in combination with letrozole, as a first-line treatment for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) postmenopausal ...
Han Fu, Zhuo-Xun Wu, Zi-Ning Lei, Zi-Ning Lei, Qiu-Xu Teng, Yuqi Yang, Charles R. Ashby, Yixiong Lei, Yuyin Lian, Zhe-Sheng Chen   +9 more
doaj   +1 more source

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan

Breast, 2023
Purpose: The optimal treatment following endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has not been established. We aimed to investigate treatment patterns and time to treatment failure (TTF) of subsequent therapy after ...
Masataka Sawaki, Yasuaki Muramatsu, Kanae Togo, Hiroji Iwata   +3 more
doaj   +1 more source

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

Cancer Biology & Therapy, 2023
Background Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the ...
Cha Len Lee, Mattia Cremona, Angela Farrelly, Julie A. Workman, Sean Kennedy, Razia Aslam, Aoife Carr, Stephen Madden, Brian O’Neill, Bryan T. Hennessy, Sinead Toomey   +10 more
doaj   +1 more source

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer

Zhongliu Fangzhi Yanjiu, 2022
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.
ZHENG Fangchao, DU Feng, LIU Haolin, WANG Xue, YUE Jian, YUAN Peng   +5 more
doaj   +1 more source